ORTHOVISC®

About the Manufacturer — Anika Therapeutics and the Science of Joint Preservation

ORTHOVISC® is manufactured by Anika Therapeutics, a US-based global medtech company headquartered in Bedford, Massachusetts, with a focus on joint preservation and regenerative medicine [5]. Anika’s commitment to clinical validation and regulatory compliance runs across its viscosupplement portfolio, which extends beyond ORTHOVISC® to include MONOVISC® — a single-injection HA viscosupplement — and CINGAL®, a product combining HA with a corticosteroid for acute knee OA symptom management [5]. This breadth of offering reflects a deliberate product-line strategy covering multi-injection, single-injection, and combination formats, giving procurement teams a range of Anika-manufactured options to evaluate within the same supplier relationship.

ORTHOVISC® itself is a sterile, highly purified hyaluronan product indicated for symptomatic osteoarthritis of the knee in patients whose pain has not responded adequately to conservative management [3][4]. FDA-approved under PMA P030019, it is classified as an intra-articular hyaluronan medical device and has been evaluated in peer-reviewed clinical literature across a range of knee OA presentations, from mild to more severe cases [1][2][3].

Regarding source material: original FDA patient labeling describes ORTHOVISC® as derived from rooster combs [4]. A subsequent FDA-approved supplement to the original PMA reflects a manufacturing process change to bacterial fermentation [3][5]. Practitioners reviewing sourcing history or managing patients with avian protein sensitivities should consult the current product labeling and verify lot-specific documentation with their supplier before ordering.

ORTHOVISC® Product Spotlight

Each ORTHOVISC® syringe delivers 30 mg of highly purified sodium hyaluronate in 2 mL of solution, supplied as a sterile single-use device for intra-articular knee injection [4][5].

The ORTHOVISC® treatment cycle consists of one injection per week for three to four consecutive weeks, with the total number of injections determined by the treating physician within that range [4]. The 3-injection course is reflected in current manufacturer materials as a standard weekly regimen; the 4-injection course is also documented in U.S. patient-facing information, giving clinicians flexibility to individualize care while remaining within labeled guidance [4][5].

When buying online through Medica Depot, practitioners can source ORTHOVISC® with verified LOT numbers, competitive pricing, and consistent supply to support scheduled orthovisc injection series across their patient caseload.

Ultra-High Molecular Weight HA — The Technology Behind ORTHOVISC®

Anika Therapeutics positions ORTHOVISC® as a high molecular weight hyaluronan product — a technical descriptor the manufacturer uses to differentiate the formulation within the viscosupplement category [5]. In knee osteoarthritis, endogenous hyaluronic acid concentration and molecular weight decrease over time, reducing the synovial fluid’s ability to act as a lubricant and shock absorber within the knee joint [1][2]. Viscosupplementation addresses this by introducing exogenous hyaluronan into the joint space, with the aim of restoring lubrication and cushioning properties that OA has degraded [1][2].

ORTHOVISC® is a sterile mixture of highly purified hyaluronan; current manufacturer positioning identifies its source as bacterial fermentation following an FDA-approved PMA supplement reflecting a manufacturing process change from the avian-derived source referenced in original patient labeling [3][4][5]. This means what ORTHOVISC® is made of has evolved through its regulatory history, and practitioners should review current lot documentation for sourcing confirmation.

The product has been evaluated in clinical studies supporting its use in knee OA pain management, including a randomized, controlled, multicenter trial demonstrating improvements in symptoms in patients treated with the product [1].

Treatment Indications — Who Is ORTHOVISC® For?

ORTHOVISC® is indicated for patients with osteoarthritis of the knee who have not achieved adequate relief from exercise, physical therapy, or simple pain medications [3][4]. In daily practice, that typically describes adults presenting with persistent knee pain, joint stiffness, and reduced mobility who remain candidates for non-surgical management or are seeking to delay surgical intervention such as total knee replacement [1].

Under U.S. FDA labeling, safety and effectiveness have not been demonstrated in joints other than the knee [4]. Off-label use in other articulations should be guided by clinical judgment, appropriate informed consent, and an understanding that such applications fall outside the product’s labeled indication. The orthovisc injection series fits naturally within a stepwise, non-pharmacological approach to knee OA management, making it relevant across orthopedic, rheumatology, and sports medicine practice settings.

Why Licensed Practitioners Choose ORTHOVISC® Over Competing HA Products

The peer-reviewed evidence base behind ORTHOVISC® spans more than two decades of clinical investigation in knee OA, including a randomized, controlled, multicenter trial demonstrating meaningful symptom improvements and a separate ORTHOVISC® Study Group evaluation of intraarticular sodium hyaluronate efficacy and safety [1][2]. That accumulated documentation gives practitioners a well-supported reference point when discussing viscosupplementation with patients, presenting options to payers, or justifying formulary decisions — a practical advantage that newer products with thinner evidence trails cannot yet match.

Beyond the clinical record, the weekly multi-injection course structure suits workflows where monitoring patient response across a treatment series is operationally or clinically preferred over a single-visit commitment. For practices that have already built reimbursement workflows, scheduling protocols, and patient communication around the ORTHOVISC® model, continuity with an established product carries real administrative value [5]. Anika’s broader portfolio also means practitioners who stock ORTHOVISC® are already working with a supplier whose single-injection and combination HA products can complement it within the same formulary when patient circumstances call for a different format.

ORTHOVISC® vs Competing Viscosupplements — A Comparison

ORTHOVISC® vs EUFLEXXA®

Both ORTHOVISC® and EUFLEXXA® are sodium hyaluronate viscosupplements used in knee OA management, and both have undergone manufacturing updates in their regulatory histories. Anika’s current manufacturer positioning describes ORTHOVISC® as high molecular weight HA, while EUFLEXXA® is a standard-to-high MW product derived from bacterial fermentation [5].

For practices that buy EUFLEXXA® alongside ORTHOVISC®, the comparison typically comes down to physician MW preference, injection scheduling, and formulary familiarity rather than a clear clinical hierarchy between the two.

ORTHOVISC® vs SYNVISC®

SYNVISC® is an avian-derived, cross-linked hylan G-F 20 formulation with a different rheologic profile and molecular structure from ORTHOVISC® [1]. SYNVISC-ONE® also offers a single-injection option within the same product family. Given ORTHOVISC®’s manufacturing history — original labeling referenced avian-derived HA, with a subsequent supplement reflecting a process change to fermentation — practitioners managing patients with avian sensitivities should verify current lot-specific documentation for both products before making sourcing decisions [3][4]. Practitioners evaluating both can buy SYNVISC® at Medica Depot.

ORTHOVISC® vs MONOVISC®

ORTHOVISC® and MONOVISC® share the same Anika Therapeutics HA technology platform, making the comparison more straightforward than most in this category [5]. ORTHOVISC® is administered over three to four weekly injections; MONOVISC® delivers a complete treatment cycle in a single injection. Practices that buy MONOVISC® alongside ORTHOVISC® can offer both treatment formats through Medica Depot, enabling patient-level selection based on compliance preference, scheduling, and payer coverage.

ORTHOVISC® vs HYALGAN®

HYALGAN® is an avian-derived, lower MW sodium hyaluronate administered over three to five weekly injections [1]. ORTHOVISC® is positioned by its manufacturer as a high MW product, and its current manufacturing process has been updated through an FDA-approved supplement [3][5]. The comparison is relevant for practices evaluating molecular weight positioning and course length simultaneously. Practitioners can buy HYALGAN® through Medica Depot and assess both products within the same procurement account.

ORTHOVISC® vs SUPARTZ®

SUPARTZ® is an avian-derived sodium hyaluronate delivered across three to five weekly injections [1]. MW profile, injection course length, and sourcing history are the primary distinguishing factors when comparing it with ORTHOVISC®. Practitioners weighing both options in the context of their patient population and payer mix can buy SUPARTZ® at Medica Depot alongside ORTHOVISC®.

How ORTHOVISC® Is Administered — Protocol and Clinical Considerations

ORTHOVISC® is administered by a qualified healthcare professional as a weekly intra-articular knee injection, with a full treatment cycle of three to four consecutive injections [4]. Any joint effusion should be aspirated before each injection to optimize intra-articular distribution of the hyaluronan solution [4]. After each orthovisc shot, patients are advised to avoid strenuous or prolonged weight-bearing activities — including jogging, tennis, heavy lifting, and extended standing — for 48 hours following the procedure [4].

According to manufacturer promotional materials, pain relief may begin within one week of the first injection, with improved mobility typically building across the injection series [5]. Individual response varies, and practitioners should set realistic expectations at the start of the treatment cycle. These statements reflect manufacturer marketing materials and specific clinical trial observations rather than universally verified label claims. Practitioners should always refer patients to current product labeling and follow IFU guidance for complete administration instructions.

ORTHOVISC® Regulatory Status, Coverage, and Practice Considerations

ORTHOVISC® is FDA-approved as a medical device under PMA P030019 for the treatment of pain in osteoarthritis of the knee in patients with inadequate response to conservative therapy [3]. CMS includes ORTHOVISC® among billable hyaluronan intra-articular knee injection products; however, actual reimbursement is strictly subject to Local Coverage Determinations and individual regional criteria.

Medicare coverage may apply, but eligibility and documentation requirements are determined by local Medicare contractors rather than a single national policy — patient-level verification is required before scheduling treatment.

ORTHOVISC® Safety Profile — Adverse Events and Contraindications

Adverse events reported with ORTHOVISC® are consistent with class effects for intra-articular hyaluronan products and are primarily localized and transient [1][4]. Common injection-site reactions include pain, swelling, warmth, rash, itching, bruising, redness, and a general aching sensation; available patient information describes these as generally mild and short-lived [4]. Serious adverse events are uncommon; practitioners should be alert to signs of acute local joint reaction and advise patients to contact their provider if symptoms worsen or persist beyond the expected recovery window [1][4].

Contraindications include known hypersensitivity to hyaluronate products, active joint infection, and skin disease or breakdown at the proposed injection site [4]. Practitioners should review the full contraindication and precaution information in the current ORTHOVISC® IFU before administering.

Medica Depot supplies ORTHOVISC® 30 mg/2 mL prefilled syringes at competitive wholesale prices for licensed practitioners, with group buy options, fast shipping, and verifiable LOT numbers. Purchase ORTHOVISC® or buy ORTHOVISC® wholesale — check for wholesale buying options or add to cart today. Practices consolidating injectable procurement can also buy hyaluronic acid dermal fillers and buy dermal fillers through the same platform.

FAQs

What makes ORTHOVISC® a multi-visit viscosupplement?

ORTHOVISC® is administered as a series of intra-articular knee injections given over consecutive weeks rather than as a single-dose treatment. This structure allows clinicians to monitor tolerance and symptom response throughout the treatment course [4].

Why should joint effusion be assessed before an ORTHOVISC® injection?

Current administration guidance recommends aspirating excess joint fluid before injection when clinically appropriate. Addressing effusion first can help ensure proper intra-articular delivery and gives the clinician an opportunity to reassess the condition of the knee before treatment [4].

What should patients avoid after receiving ORTHOVISC®?

Patients are generally advised to avoid strenuous or prolonged weight-bearing activity for around 48 hours after treatment. Post-injection guidance may also include temporary modification of exercise and activity depending on soreness, swelling, and the clinician’s instructions [4].

How should clinicians assess response to ORTHOVISC®?

Pain intensity, mobility, functional limitations, and patient-reported improvement can be tracked during and after the injection series. Because benefit may build gradually, follow-up assessment is more useful than judging treatment success immediately after the first injection [5].

Why does the manufacturing source of ORTHOVISC® matter?

ORTHOVISC® labeling has reflected changes in its manufacturing process over time, including a transition documented through an FDA-approved PMA supplement. Practitioners should confirm the current source, formulation details, and lot-specific documentation rather than relying on older product descriptions [3][4][5].

Can ORTHOVISC® fit into a broader knee OA management plan?

Yes. ORTHOVISC® may be incorporated alongside other osteoarthritis management strategies such as exercise, physical therapy, weight management, and analgesic use. The decision to use viscosupplementation should depend on prior treatment response and overall clinical assessment.

What should practices verify before billing ORTHOVISC®?

Billing teams should confirm the current HCPCS product code, procedure code, units, medical-necessity requirements, authorization rules, and any applicable Local Coverage Determination before treatment. Coverage criteria can vary by payer and region.

What should clinics review when ordering ORTHOVISC® wholesale?

Practices planning to order ORTHOVISC® wholesale through Medica Depot should review pack configuration, expected patient volume, storage requirements, expiration dates, LOT information, shipping conditions, and available group-buy pricing before placing an order.

Disclaimer

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.

Citations

[1] Neustadt D, Caldwell J, Bell M, Wade J, Gimbel J. Clinical effects of intraarticular injection of high molecular weight hyaluronan (Orthovisc) in osteoarthritis of the knee: a randomized, controlled, multicenter trial. The Journal of Rheumatology. 2005;32(10):1928–1936. https://pubmed.ncbi.nlm.nih.gov/16206349/

[2] Brandt KD, Block JA, Michalski JP, Moreland LW, Caldwell JR, Lavin PT. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group. Clinical Orthopaedics and Related Research. 2001. https://pubmed.ncbi.nlm.nih.gov/11302304/

[3] U.S. Food and Drug Administration. P030019 — Premarket Approval (PMA): ORTHOVISC®. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P030019

[4] U.S. Food and Drug Administration. Patient Information ORTHOVISC® High Molecular Weight Hyaluronan. FDA. https://www.accessdata.fda.gov/cdrh_docs/pdf3/p030019d.pdf

[5] Anika Therapeutics. Orthovisc for Knee OA Pain Relief. https://anika.com/products/oapm/orthovisc/